Arcturus Therapeutics (NASDAQ:ARCT) Research Coverage Started at BTIG Research

BTIG Research initiated coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report published on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $41.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on ARCT. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a report on Monday, January 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $61.60.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $17.42 on Tuesday. Arcturus Therapeutics has a one year low of $14.30 and a one year high of $45.00. The stock’s 50-day moving average is $17.26 and its 200-day moving average is $19.54. The firm has a market cap of $471.91 million, a P/E ratio of -7.85 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the previous year, the company posted ($0.61) earnings per share. Equities analysts anticipate that Arcturus Therapeutics will post -2.31 EPS for the current year.

Institutional Trading of Arcturus Therapeutics

Several large investors have recently made changes to their positions in ARCT. Sumitomo Mitsui Trust Group Inc. increased its position in Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Millennium Management LLC boosted its holdings in Arcturus Therapeutics by 250.1% in the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after acquiring an additional 396,505 shares during the last quarter. Empire Life Investments Inc. bought a new position in Arcturus Therapeutics during the third quarter worth $3,498,000. ARK Investment Management LLC raised its position in shares of Arcturus Therapeutics by 6.9% in the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after acquiring an additional 136,074 shares in the last quarter. Finally, PDT Partners LLC bought a new stake in shares of Arcturus Therapeutics in the 3rd quarter valued at $1,744,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.